title: Are we ready to change clinical practice after the 'soft and text' results?
authors.affiliation: Experimental Department, Sapienza University of Rome, Rome, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: De Iuliis
authors.affiliation: Policlinico Umberto I Hospital, Rome, Italy.
authors.forename: Rosina
authors.initials: R
authors.lastname: Lanza
authors.affiliation: Experimental Department, Sapienza University of Rome, Rome, Italy.
authors.forename: Susanna
authors.initials: S
authors.lastname: Scarpa
mesh_terms: D000730:Androstadienes / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic; D019468:Disease Management; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015337:Multicenter Studies as Topic; D010818:Practice Patterns, Physicians'; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D007987:Gonadotropin-Releasing Hormone; C056516:exemestane
keywords: aromatase inhibitors; breast cancer; exemestane; triptorelin